Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21 755 patients from the Japanese breast cancer registry

Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: Based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011

(2015) Junichi Kurebayashi et al.   Breast Cancer

Comparative Effectiveness of Neoadjuvant Therapy for HER2–Positive Breast Cancer: A Network Meta-Analysis

(2014) Aiko Nagayama et al.   JNCI-Journal of the National Cancer Institute

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

(2014) Patricia Cortazar et al.   LANCET

Challenges and prospects of a clinical database linked to the board certification system

(2014) Hiroaki Miyata et al.   SURGERY TODAY

Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients

(2013) V. Guarneri et al.   ANNALS OF ONCOLOGY

Reliability of core needle biopsy for determining ER and HER2 status in breast cancer

(2012) T. J. A. Dekker et al.   ANNALS OF ONCOLOGY

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

(2012) Gunter von Minckwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors

(2011) Naoki Niikura et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

(2010) Luca Gianni et al.   LANCET

Estrogen and HER-2 Receptor Discordance Between Primary Breast Cancer and Metastasis

(2010) L. Pusztai et al.   ONCOLOGIST

Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?

(2009) C. Simmons et al.   ANNALS OF ONCOLOGY

Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes

(2009) E. A. Mittendorf et al.   CLINICAL CANCER RESEARCH

Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations

(2009) Guido Sauter et al.   JOURNAL OF CLINICAL ONCOLOGY

HER-2/neu expression in primary and metastatic breast cancer

(2008) Elyse E. Lower et al.   BREAST CANCER RESEARCH AND TREATMENT

Presurgical Systemic Treatment of Nonmetastatic Breast Cancer: Facts and Open Questions

(2008) A. Berruti et al.   ONCOLOGIST